# Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer

> **NCT05916261** · EARLY_PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 54 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Personalized neoantigen tumor vaccine

## Key facts

- **NCT ID:** NCT05916261
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-26
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05916261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05916261, "Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05916261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*